Celltrion launches Omlyclo, first interchangeable biosimilar to Xolair, in US

Celltrion began the U.S. launch of Omlyclo on October 5, 2026 as the first interchangeable biosimilar to Genentech's Xolair, at a 15% discount and with no pending patent dispute, alongside the launch of Filkri, a Neupogen biosimilar.